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A B S T R A C T
Vitamin C (VitC) possesses pro-oxidant properties at high pharmacologic concentrations which favor re-
purposing VitC as an anti-cancer therapeutic agent. However, redox-based anticancer properties of VitC are yet
partially understood. We examined the difference between the reduced and oxidized forms of VitC, ascorbic acid
(AA) and dehydroascorbic acid (DHA), in terms of cytotoxicity and redox mechanisms toward breast cancer cells.
Our data showed that AA displayed higher cytotoxicity towards triple-negative breast cancer (TNBC) cell lines in
vitro than DHA. AA exhibited a similar cytotoxicity on non-TNBC cells, while only a minor detrimental effect on
noncancerous cells. Using MDA-MB-231, a representative TNBC cell line, we observed that AA- and DHA-in-
duced cytotoxicity were linked to cellular redox-state alterations. Hydrogen peroxide (H2O2) accumulation in the
extracellular medium and in different intracellular compartments, and to a lesser degree, intracellular glu-
tathione oxidation, played a key role in AA-induced cytotoxicity. In contrast, DHA affected glutathione oxidation
and had less cytotoxicity. A “redoxome” approach revealed that AA treatment altered the redox state of key
antioxidants and a number of cysteine-containing proteins including many nucleic acid binding proteins and
proteins involved in RNA and DNA metabolisms and in energetic processes. We showed that cell cycle arrest and
translation inhibition were associated with AA-induced cytotoxicity. Finally, bioinformatics analysis and bio-
logical experiments identified that peroxiredoxin 1 (PRDX1) expression levels correlated with AA differential
cytotoxicity in breast cancer cells, suggesting a potential predictive value of PRDX1. This study provides insight
into the redox-based mechanisms of VitC anticancer activity, indicating that pharmacologic doses of VitC and
VitC-based rational drug combinations could be novel therapeutic opportunities for triple-negative breast
cancer.
1. Introduction
Reactive oxygen species (ROS) homeostasis and intracellular re-
ductive/oxidative (redox) dynamics play a key role in regulating cell
viability or death. Mounting evidence has established that defects in
redox signaling and oxidative stress are at the crux of various patho-
logical processes. Notably, one of the significant features of cancer cells,
when compared to their normal counterparts, is a persistent pro-oxi-
dative state. In cancer cells, cellular events such as activation of on-
cogenes, aberrant metabolic stress and mitochondrial dysfunction can
increase ROS levels, leading to intrinsic oxidative stress [1,2]. There-
fore, the administration of a ROS-generating agent or antioxidant in-
hibitor could increase ROS levels to a threshold that is incompatible
with viability, selectively and preferentially affecting cancer cells
[1–3].
Vitamin C (VitC) is an essential nutrient used as a co-factor by nu-
merous biosynthetic enzymes. It exists in the parental reduced form or
ascorbic acid (AA, or AscH2) and the oxidized forms, encompassing the
ascorbate radical (Asc•–) and the dehydroascorbic acid (DHA). At phy-
siological pH (7.0), the dominant species for VitC is ascorbate
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monoanion (AscH−, 99.9%), with low concentrations of AscH2 (0.1%)
and ascorbate dianion (Asc2−, 0.005%) [4]. The ability to donate one
or two electrons makes ascorbate (AscH−) an excellent reducing agent
and antioxidant. At millimolar levels (pharmacologic concentrations),
AA becomes a ROS-generating molecule. In fact, a small portion of AA,
via the ascorbate dianion (Asc2−), can undergo limited pH-dependent
auto-oxidation that can lead to superoxide anion (O2•–) formation ac-
cording to the following reaction: Asc2− + O2 → Asc•– + O2•– [4,5].
Superoxide anions subsequently dismute to produce H2O2
(O2•– + O2•– + 2H+ → H2O2 + O2). Importantly, in the presence of
redox active metal ions, AA oxidation is further accelerated and am-
plified as ascorbate (AscH−) can exert an additional pro-oxidant effect.
AscH− donates one electron to metals, that can reduce ferric (Fe3+) to
ferrous (Fe2+) iron for example, while being oxidized to ascorbate ra-
dical (AscH– + Fe3+ → Asc•– + Fe2+ + H+). Fe2+ can readily react
with O2, reducing it to superoxide anion (O2 + Fe2+ → O2•– + Fe3+),
which in turn dismutes to H2O2 and O2 [4,5]. These mechanisms act to
produce a high flux of H2O2 at pharmacologic concentrations of AA. In
a classic Fenton reaction, Fe2+ reacts with H2O2 to generate Fe3+ and
the highly reactive hydroxyl radical.
H2O2 generated in the extracellular medium or extracellular fluids
appears to be the central player for pro-oxidant properties of AA at
pharmacologic concentrations, achievable in cell culture experiments,
and in vivo by intravenous administration. Extracellular H2O2 readily
diffuses into cells; if not removed, it can lead to oxidative damage to
proteins, lipids, and DNA. On the other hand, it is expected that AA,
upon import through plasma membranes via sodium-dependent VitC
transporters (SVCTs), can generate intracellular H2O2 directly by the
same metals-catalyzed reactions described above. In accordance, AA
cytotoxicity was observed in a number of studies in vitro and in vivo
models on cancer cells from different origins without adversely af-
fecting normal cells [6–8]. Such cytotoxicity was also dependent on
redox metal supply such as iron [9]. VitC anticancer effects driven by its
DHA form were also reported [10]. Yun et al. observed that VitC was
oxidized to DHA in cell culture media lacking reducing agents, and was
subsequently imported into human colon cancer cells harboring onco-
genic KRAS or BRAF mutations by overexpressed GLUT1 glucose
transporter. Following import, DHA is reduced to AA at the expense of
glutathione (GSH) and NADPH. Increased DHA uptake leads to GSH
oxidation, thus indirectly promoting endogenous ROS accumulation
and specific inactivation of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), and consequently, impairing glycolysis and inducing cancer
cell death [10].
Several studies addressed the question regarding VitC selective cy-
totoxicity toward cancer cell lines. Differential ability to metabolize
H2O2 between normal and pancreatic cancer cells were shown to be
determinant in AA effect on pancreatic cancer cells while sparing
normal ones in vitro and in vivo [11]. In addition, a positive correlation
between the sodium-dependent VitC transporter 2 (SVCT2) expression
and AA cytotoxicity were reported in breast cancer cells, cholangio-
carcinoma cell lines and patient-derived xenografts [12–14]. Interest-
ingly, a recent study showed that non-small-cell lung cancer and
glioblastoma cells are selectively sensitive to AA due to their altered
redox-active iron metabolism, resulted from altered mitochondrial
oxidative metabolism and increased levels of O2•– and H2O2 [15]. The
same team found similar benefits of pharmacological ascorbate in
preclinical models of fibrosarcoma and liposarcoma [16]. Finally, dif-
ferent energy metabolisms between cancer and normal cells, known as
the Warburg effect where cancer cells strongly depend on glycolysis for
their energy and ATP production, render cancer cells far more vulner-
able to glycolysis impairment by VitC than their normal counterparts
[10,17,18].
Pharmacologic dose of AA enhanced chemosensitivity of ovarian
cancer to carboplatin and paclitaxel and reduced toxicity of che-
motherapy in mouse models [19]. AA also enhanced sensitivity to io-
nizing radiation by increasing H2O2-mediated DNA damage in pan-
creatic cancer model [20,21], and in prostate cancer cells while sparing
normal cells from radiotoxicity [22]. Clinical studies revealed that
pharmacologic doses of AA were well tolerated and increased the effi-
cacy of conventional radio-chemotherapy in non-small-cell lung cancer
and glioblastoma patients [15], and in pancreatic cancer patients [23].
These recent studies reflect a regained interest in VitC anticancer
activity. However, VitC redox-based anticancer mechanisms warrant
further investigation. Notably, which form of VitC exhibits the higher
anticancer activity? Is this effect cell-type dependent? What are the
factors that condition cellular sensitivity to VitC? What are the key
intermediates (H2O2 or GSH oxidation) that lead to cell death? And
which proteins or pathways are key targets of VitC-mediated oxidation?
In this study we provide answers to these questions using breast cancer
model.
2. Materials and methods
2.1. Cell culture
Triple-negative breast cancer (TNBC) cell lines MDA-MB-231 and
HTB-26, human umbilical vein endothelial cells (HUVEC) and human
dermal fibroblasts (PCS-201-012) were purchased from American Type
Culture Collection. Human mammary epithelial cells (HMEC) were
purchased from Lonza. Additional breast cancer cell lines were obtained
from the Translational Research Department of the Institut Curie (Paris,
France). MDA-MB-231, MDA-MB-468, MDA-MB-436, BT-549, HCC-
1937, BT-20, MDA-MB-453, MDA-MB-134, MDA-MB-415, HUVEC and
fibroblasts cells were grown in DMEM (Eurobio) supplemented with
10% FBS, 2mM L-glutamine, 1X non-essential amino acids, 1 mM so-
dium pyruvate and 100 U/ml penicillin and 100 μg/ml streptomycin.
HCC-1187, HCC-1954, T47D, HCC-1428 were grown in RPMI medium
supplemented with 10% FBS, 2mM L-glutamine 100 U/ml penicillin
and 100 μg/ml streptomycin. HMEC were grown in mammary epithelial
basal medium (MEBM) supplemented with MEGM SingleQuots (Lonza)
(containing bovine pituitary extract, hydrocortisone, hEGF, insulin and
gentamicin/amphotericin-B), 10% FBS and 100 U/ml penicillin and
100 μg/ml streptomycin. Cells are incubated in humidified atmosphere
at 37 °C with 5% CO2 in air and were routinely checked for the absence
Abbreviations
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of mycoplasma. Cell lines were authenticated using standard DNA mi-
crosatellite short tandem repeat (STR) method.
2.2. Drugs and reagents
L-ascorbic acid (AA), L-dehydroascorbic acid (DHA), N-ethylmalei-
mide (NEM), crystal violet, N-acetyl-L-cysteine (NAC), glutathione,
DMSO, dithiothreitol (DTT), hydrogen peroxide (H2O2), catalase, dia-
mide, trichloroacetic acid (TCA) and cycloheximide were purchased
from Sigma-Aldrich. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT), 6-carboxy-2′,7′-dichlorodihydrofluorescein
diacetate (carboxy-H2DCFDA), 5-bromo-2′-deoxy-uridine (BrdU) and
propidium iodide (PI) were from Thermo Fisher Scientific. The fol-
lowing antibodies were used: anti-PRDX3 (Abcam), anti-GFP (Life
Technologies), anti-β-actin (Sigma-Aldrich), anti-PRDX1 (Cell Signaling
Technology), FITC Mouse anti-BrdU (BD Biosciences).
2.3. ROS assessment, H2O2 detection and H2O2 quantification
General ROS were assessed using carboxy-H2DCFDA staining and a
FACSCalibur flow cytometer (Becton Dickinson) and data were ana-
lyzed using Flowjo software. For compartment-specific H2O2 detection,
mammalian expression vectors encoding HyPer targeted to nucleus
(with a nuclear localization signal), and mitochondria (with a mi-
tochondrial matrix localization signal) were purchased from Evrogen.
HyPer targeted to the cytosol with a nuclear export signal and HyPer
targeted to the membrane using the membrane-targeting signal in
protein GAP-4 were constructed in our laboratory. Cells were trans-
fected with HyPer expressing vectors using jetPRIME reagents (Polyplus
Transfection). Further experiments were performed 24 h after trans-
fection. Analyses of oxidized and reduced forms of sensor by redox
Western blot were performed according to Ref. [24]. H2O2 concentra-
tion in the medium was quantified using the Amplex Red Hydrogen
Peroxide/Peroxidase Assay Kit (Thermo Fisher Scientific). The fluor-
escence was measured in a microplate reader (Victor3; PerkinElmer).
H2O2 concentration in the growth medium (μM) was quantified using
H2O2 standard calibration curves.
2.4. Quantitative redoxome analysis
Cells were subjected to different treatments and proteins were ex-
tracted. Purification of these proteins was performed according to a
published protocol with slight modifications [25]. Protein digests were
analyzed in triplicate with an Orbitrap Fusion Tribrid equipped with an
EASY-Spray ion source. Label-free liquid-chromatography tandem mass
spectrometry (LC-MS/MS) acquisition was performed. Peptides from
MS/MS data were processed with Proteome Discoverer Software (v 2.1)
using Sequest search node. All results were 1% FDR filtered before
exporting. The resulting files were imported into Progenesis-Qi soft-
ware for report edition. Variations of protein abundance were con-
sidered as significant if their Anova P values were<0.05. Details of the
protocol and analysis are described in Supplementary Materials and
Methods and Supplementary Fig. 1. The proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE [26]
partner repository with the dataset identifier PXD013833.
Ingenuity Pathways Analysis software (IPA, QIAGEN) was used to
classify genes onto canonical pathways, cellular and molecular func-
tions and networks. Pathways enriched with a P < 0.05 were con-
sidered to be statistically significant. More details on IPA are found
online (http://www.ingenuity.com). Database for Annotation,
Visualization and Integrated Discovery (DAVID) software (https://
david.ncifcrf.gov, Version 6.8) was used to determine and represent
functional protein classes and biological processes enriched from Gene
ontology (GO) database. Functional annotations with P < 0.05 (EASE
score) (modified Fisher's exact test) were selected.
2.5. BrdU incorporation and cell cycle analysis
BrdU incorporation and DNA staining with PI were performed using
the acid denaturation method as described previously [27]. All samples
were analyzed by a FACSCanto flow cytometer (Becton Dickinson) and
data were analyzed using Flowjo software.
2.6. Translation studies
After different treatments, cells were incubated in growth media
containing 100 μg/cycloheximide for 15min at 37 °C in order to stop
ribosomal elongation. After being washed with ice-cold 1X PBS sup-
plemented with 100 μg/ml cycloheximide, cells were scraped and har-
vested into ice-cold 1X PBS supplemented with 100 μg/ml cyclohex-
imide and pelleted by centrifugation (3000 rpm for 5min at 4 °C). The
pellets were resuspended in 400 μl of LSB buffer (20mM Tris-HCl pH
7.5, 100mM NaCl, 3 mM MgCl2, 1 mM DTT, 100 μg/ml of cyclohex-
imide, and 100 U/ml of RNAsin) and lysed by adding 400 μl of LSB
buffer containing 2.4% Triton X-100 and 0.5M sucrose. The lysates
were centrifuged (12000 g for 5min at 4 °C), and the supernatants were
recovered and adjusted with additional 50 μl of LSB buffer containing
NaCl and MgCl2 with quantities that enable final concentrations of
50mM NaCl and 7mM MgCl2. Then, supernatants were layered onto
15–50% sucrose gradients in LSB buffer, centrifuged (38,000 rpm for
2 h at 4 °C) and 18 fractions were collected with a fraction collector.
For nonpolysomal RNA (fractions 1 to 8, containing ribosomal RNAs
present in 40S, 60S, and 80S ribosomal complexes, and free mRNAs)
and polysomal RNA (fractions 9 to 18, containing mRNAs bound to
more than one ribosome), the optical density of these fractions (OD
254 nm) were determined.
2.7. Transcriptomic data analysis
Genes expression data were extracted from two publicly accessible
transcriptomic datasets: NCI-60 CellMiner Database (https://discover.
nci.nih.gov/cellminer/Database Version: 2.1) and affymetrix normal-
ized data for breast cancer cell lines of the Institut Curie collection
(http://microarrays.curie.fr/publications/recherche_translationnelle/
plateforme_genomique/). Using NCI-60 CellMiner Database, each gene
transcript Z-score (input HUGO name) and gene name were used as
input identifier. The data file retrieved contained the average log2 in-
tensity and Z-score of each gene expression in 60 cell lines. Using the
Institut Curie database, gene mRNA expression levels (log2) for 29
breast cancer cell lines were retrieved.
2.8. Miscellaneous methods
MTT-based cell viability assay was performed as previously de-
scribed [28]. For colony formation assays, cells were plated in 6-well
plates in a density of 1000/well and treated under defined conditions
and then further cultured for 14 days. Afterwards, colonies were fixed
by ethanol, stained with crystal violet solution and counted using Im-
ageJ software. For siRNA transfection, cells were transfected with
20 nM siRNA (ON-TARGET plus SMART pool siRNA or control siRNA,
Dharmacon) using INTERFERin reagents (Polyplus Transfection). Fur-
ther experiments were performed 48 h after transfection. Classical
western blots and redox western blots were performed as described
previously [24]. Total cellular glutathione levels (GSH + GSSG), GSSG
(oxidized form) and GSH/GSSG ratios were assessed using GSH/GSSG-
Glo™ Assay (Promega). Luminescence was read using TriStar2 LB 942
Modular Monochromator Multimode Reader (Berthold technologies).
Data were presented by GSH/GSSG ratios.
2.9. Statistical analysis
Statistical significance of each data set was analyzed using adequate
N. El Banna, et al. Redox Biology 26 (2019) 101290
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statistical tests available in the GraphPad Prism 7 software and speci-
fied in the body of manuscript and figure legends. Data were presented
as the mean ± standard deviation (SD). Dose-response modeling, half-
maximal inhibitory concentration (IC50) determination from MTT cell
viability assays and Spearman's correlation analyses were also per-
formed using the GraphPad Prism 7 software (GraphPad Software, Inc).
Wherever possible, exact P values are given and P < 0.05 were con-
sidered statistically significant.
3. Results
3.1. AA shows higher cytotoxicity toward breast cancer cells than DHA
without affecting noncancerous cells
A panel of 7 TNBC cell lines was exposed to increasing concentra-
tions of AA and DHA. MTT assays showed that TNBC cells displayed
different sensitivity to AA treatment for 24 h (Fig. 1A). At pharmaco-
logic concentrations, MDA-MB-231 cells, among others (HCC-1187,
BT549, MDA-MB-468, HCC-1937 and BT20), were highly sensitive to
AA ranging from 7mM to 10mM (4–20% viability at 10mM AA); while
MDA-MB-436 showed more resistance (~70% viability at 10mM AA).
Less cytotoxicity was observed with DHA for all TNBC cells in the same
treatment conditions. Only 3 cell lines (HCC-1187, BT20 and MDA-MB-
231) were sensitive to 10mM DHA treatment for 24 h (7–40% viability)
(Fig. 1B). Upon AA and DHA treatments for 24 h, MTT assays and
clonogenic assay confirmed that VitC-induced cytotoxicity was asso-
ciated with a loss of the ability to form colonies and that AA displayed
stronger cytotoxicity than DHA (Fig. 1C). In addition, we determined
the sensitivity of 6 non-TNBC cell lines to AA-treatment for 24 h
(Fig. 1D). Five of them (MDA-MB-134, T47D, HCC-1428, MDA-MB-415
and MDA-MB-453) were sensitive to 10mM AA treatment (5–35%
viability) while HCC-1954 showed more resistance (~80% viability).
Finally, noncancerous cell lines including HMEC, human dermal fi-
broblasts and HUVEC showed a high survival rate even at 10mM AA
treatment (60–80%) (Fig. 1E).
3.2. H2O2 generation and GSH oxidation underlie AA-induced cytotoxicity
while GSH oxidation plays a partial role in DHA-induced lower cytotoxicity
In order to understand the mechanism of action of AA and DHA, we
used MDA-MB-231 cells, one representative TNBC cell line that is
commonly studied in literature, to evaluate the redox alteration in-
duced by VitC treatments. For this purpose, two concentrations of VitC
were further used, the non-cytotoxic 2.5 mM and the cytotoxic 10mM.
Since DHA was shown to be responsible for GSH oxidation upon in-
creased uptake through the glucose transporter GLUT1 in colorectal
cancer model [10], we first determined the reduced and oxidized levels
of this main cellular antioxidant after AA and DHA treatments in MDA-
MB-231 cells. As shown in Fig. 2A, a significant decrease in GSH/GSSG
ratios, indicating GSH oxidation, is observed after 2-h treatment with
10mM AA or DHA but not with 2.5mM. Next, we performed a general
ROS assessment using carboxy-H2DCFDA. A 2-fold increase in fluores-
cence intensity was detected upon treatment for 4 h with 10mM but not
with 2.5 mM AA (Fig. 2B). Co-treatment with 10mM AA and either
catalase or GSH abolished the increase in the fluorescence intensity
Fig. 1. Sensitivity of TNBC, non-TNBC and noncancerous cells toward AA and DHA. (A-B) Seven TNBC cell lines were treated with AA (A) or DHA (B) ranging
from 0 to 10mM for 24 h. Cell viability (%) relative to non-treated condition was measured with MTT assay for each cell line. Data are means ± SD of at least 6
independent experiments. Statistical significance is assessed by two-way ANOVA with Sidak's multiple comparisons test. (C) MDA-MB-231 cells were treated with AA
or DHA for 24 h. Cell viability (%) relative to non-treated condition was measured by MTT assay (left panel). Data are means ± SD of at least 6 independent
experiments. Representative images of colonies formation of MDA-MB-231 cells after AA or DHA treatments for 24 h are shown (right panel). (D) Six non-TNBC cells
were treated with AA ranging from 0 to 10mM for 24 h. Cell viability (%) relative to non-treated condition was measured with MTT assay. Data are means ± SD of
at least 6 independent experiments. Statistical significance is assessed by two-way ANOVA with Sidak's multiple comparisons test. (E) HMEC, normal human dermal
fibroblasts and HUVEC were treated with AA ranging from 0 to 10 mM for 24 h. Cell viability (%) relative to non-treated condition was measured with MTT assay for
each cell line. Data are means ± SD of 4 independent experiments. Statistical significance is assessed by ordinary two-way ANOVA with Tukey's multiple com-
parisons test. ****, P < 0.0001.
(caption on next page)
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observed. In contrast, 10mM DHA did not result in change in fluores-
cence intensity that was not affected either by the presence of catalase
or GSH (Fig. 2B). This indicates that cytotoxic dose of AA treatment, but
not DHA, induces general intracellular ROS accumulation.
We then questioned the link between these redox alterations and
VitC cytotoxicity. Noticeably, AA-induced cytotoxicity in MDA-MB-
231 cells could be totally or largely suppressed by the presence of either
catalase, NAC or GSH (Fig. 2C). NAC serves as a prodrug to L-cysteine
which is a precursor to GSH. On the other hand, DHA-induced cell
death was not rescued by catalase, while partially by GSH or NAC, with
mean cell viability 58% and 61% respectively. These observations in-
dicate the role of H2O2 generation and GSH oxidation in AA cytotoxicity
and a partial implication of GSH oxidation in DHA cytotoxicity.
To further verify the generation of H2O2 in AA-treated condition, we
used Amplex-Red Kit to measure H2O2 concentration in the medium.
After 10mM AA treatment for 5min, ½ hour and 2 h, H2O2 con-
centrations in the medium with or without MDA-MB-231 cells increased
more than 20 times (Fig. 3A). Furthermore, the co-treatment by AA and
catalase abolished H2O2 accumulation, validating the extracellular
generation of H2O2 by AA. Next, we used genetically encoded HyPer
sensors addressed to several cellular compartments in MDA-MB-
231cells to determine whether H2O2 accumulated intracellularly in one
or more cellular compartments. HyPer sensors specifically react with
H2O2 [29,30]. Cytoplasm-localized HyPer oxidation was visible in
presence of 10mM AA for 5min, ½ hour and 2 h, indicating a con-
tinuous H2O2 accumulation in the cytoplasm of the cells upon AA
treatment (Fig. 3B). The same results were obtained with nucleus-,
mitochondrial matrix- and membrane-targeted HyPer. Furthermore, co-
treatment with AA and catalase abolished the oxidation of HyPer. Fi-
nally, the redox states of two compartment-specific antioxidant pro-
teins, cytoplasmic PRDX1 and mitochondrial PRDX3, were analyzed by
redox Western blot. Cytotoxic dose of AA (10mM) increased PRDX3
oxidation (50–60% dimer) and PRDX1 oxidation (~10% dimer) after
5min, ½ hour and 2 h of treatment, indicating mitochondrial and cy-
tosolic H2O2 accumulation (Fig. 3C). These data are in agreement with
an important role of H2O2 in AA-induced cytotoxicity.
3.3. AA treatment alters the redox state of cysteine-containing proteins
Our observations described above linked AA cytotoxicity to extra-
cellular and intracellular H2O2 accumulation and showed the redox
state alteration of some cysteine-containing antioxidants upon AA
treatment. As many proteins with highly reactive cysteine residues are
implicated in different critical pathways and could be impacted by
H2O2, we decided to examine the alterations of the redoxome, the
oxidized proteome of cysteine-containing proteins, by redox mass
spectrometry approach [31,32]. Using a biotin switch approach that
allows the enrichment of proteins containing oxidized thiols [25], we
compared the redoxome of non-treated and treated (10mM AA, ½
hour) MDA-MB-231 cells in two independent biological replicates, each
with three technical replicates (Supplementary Fig. 1). Upon short AA
treatment, we expected to identify early events in cellular response to
AA that might be linked to AA-induced cell death.
Quantitative proteomic analysis by LC-MS/MS allowed the identi-
fication of 2910 cysteine-containing proteins. Among them, 203 pro-
teins (6.97%) were commonly identified in both biological experiments
and exhibited a significant change in cysteine oxidation levels between
non-treated and treated cells (over 1.5-fold in at least one of the two
biological experiments with P < 0.05) (Supplementary Table 1).
38.42% of these proteins were more oxidized while 61.58% were more
reduced in 10mM AA-treated cells compared to the non-treated con-
dition. The high proportion of more reduced proteins following AA
treatment is intriguing but could be explained by the fact that in-
tracellularly AA could not only generate H2O2 but also act as a con-
ventional reducing agent, generating both oxidized and reduced pro-
teins upon AA treatment. Compartment-specific redox response could
also be taken into account. Proteins in some compartments could be
more oxidized while those in other compartments could be more re-
duced through antioxidant system response against the AA-induced
H2O2 and oxidative stress, thus protecting some important cellular
signaling pathways and proteins from oxidation.
As expected, antioxidant enzymes including glutathione S-trans-
ferase Mu 3 (GSTM3), γ-glutamylcyclotransferase (GGCT) and PRDX1
were among the identified oxidized targets of AA treatment
(Supplementary Table 1), compromising antioxidant capacity. On the
other hand, proteins belonging to the glycolysis and gluconeogenesis
pathway (PYGM, PGK1), and tricarboxylic acid cycle (ACOT7, DLAT,
FADS2), exhibited also a significant increase in oxidation upon AA
treatment. Thus, energetic metabolism enzymes were also among the
targets of AA, in accordance with the energetic crisis and metabolic
alterations described in other studies [33]. Interestingly, several pro-
teins implicated in DNA and RNA metabolism as well as in protein
metabolism were oxidized in treated cells, including chromosome-as-
sociated kinesin KIF4A (accession number O95239), histone-binding
protein RBBP4 (Q09028), ATP-dependent RNA helicase DHX8
(Q14562), U5 small nuclear ribonucleoprotein 40-kDa protein
(Q96DI7), tRNA-splicing ligase RtcB homolog (Q9Y3I0), 26S protea-
some non-ATPase regulatory subunit 3 (O43242), Cullin-4A (Q13619),
E3 ubiquitin-protein ligase RING2 (Q99496), E3 ubiquitin-protein li-
gase UBR4 (Q5T4S7), E3 ubiquitin-protein ligase XIAP (P98170), and
E3 SUMO-protein ligase RanBP2 (P49792) (Supplementary Table 1).
These data indicate that AA leads to the oxidation of thiol-containing
proteins implicated in several essential cellular processes such as energy
production, nucleic acid and protein metabolisms.
IPA software for enrichment analysis of these 203 proteins differ-
entially oxidized between AA-treated and non-treated conditions re-
vealed that glucocorticoid receptor signaling and EIF2 signaling path-
ways were among the top significant canonical pathways (Fig. 4A). The
top five significantly enriched molecular and cellular pathways in-
cluded cellular assembly and organization, cellular function and
maintenance, RNA post-transcriptional modification, molecular trans-
port and RNA trafficking (Fig. 4A). These proteins’ main networks were
dominated by RNA post-transcriptional modification, cancer, cell death
and survival (Fig. 4A). Moreover, protein classification according to
their GO biological processes in DAVID database fall into categories of
cell-cell adhesion, rRNA processing, translational initiation, viral tran-
scription, and cell proliferation, among others (Fig. 4B). Taken to-
gether, redoxome data seem to point to the possible effect of AA
treatment on DNA replication and transcription/translation, among
other pathways.
Fig. 2. Glutathione oxidation and ROS generation in response to AA and
DHA treatments in MDA-MB-231 cells. (A) GSH and GSSG quantities were
assessed in non-treated cells and cells treated with 2.5 or 10mM AA or DHA for
½ hour and 2 h. Treatment with 250 μM diamide for 10min was used as a
positive control (PC). GSH/GSSG ratio value in non-treated cells is set as 1 and
relative GSH/GSSG ratios calculated in treated conditions are represented as
means ± SD of 4 independent experiments. Statistical significance is assessed
by ordinary one-way ANOVA with Tukey's multiple comparisons test. (B)
General intracellular ROS was assessed by flow cytometry using carboxy-
H2DCFDA probes in non-treated cells (NT), cells treated with 2.5 or 10mM AA
or DHA for 4 h (upper panel), cells treated with 10mM AA, 10mM AA plus
2000 U/ml catalase or 10mM AA plus 10mM GSH (lower panel). Treatment
with 100 μM H2O2 for 20min was used as a positive control (PC). Mean
fluorescence value in non-treated MDA-MB-231 cells is set as 1 and relative
fluorescence intensity is represented. Data are means ± SD of 4 independent
experiments. Statistical significance is assessed by ordinary one-way ANOVA
with Tukey's multiple comparisons test. (C) MTT assay was performed on cells
treated with 10 mM AA or DHA alone or in the presence of 2000 U/ml catalase,
10 mM NAC or 10 mM GSH for 24 h. Data are means ± SD of at least 6
independent experiments. Statistical significance is assessed by two-way
ANOVA with Tukey's multiple comparisons test. ****, P < 0.0001; **,
P < 0.01; *, P < 0.05.
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3.4. S-phase of cell cycle is affected by AA treatment
As a first attempt, we performed cell cycle analysis on MDA-MB-
231 cells upon AA treatment using BrdU. BrdU is a thymidine analogue
which can be incorporated into the DNA during replication. BrdU
staining thus allows to follow newly synthesized DNA together with
total DNA staining by PI to measure total DNA content and assign the
cells to the various stages of the cell cycle. Cells were left non-treated or
treated with 10mM AA for 2 h. Then, at various time points of post-
treatment recovery (from 0 to 24 h), cells were pulse-labeled with BrdU
followed by PI staining and FACS analysis. A significant decrease in
BrdU incorporation was observed after 2 h of AA treatment, indicating
an S-phase arrest when compared to non-treated cells (Fig. 5A and B).
To support these data, cells were first labeled with BrdU, and then
treated or not with 10mM AA for 2 h before being analyzed by FACS at
various time points during post-treatment recovery. Cells subjected to
AA treatment showed an immediate and prolonged S-phase delay
(Fig. 5C). Moreover, catalase efficiently prevented S-phase slowdown in
both conditions of BrdU pulse, post and prior AA treatment (Fig. 5A–C),
suggesting that H2O2 production is causal in the inhibition of DNA re-
plication. Taken together, these observations points to the possibility
that the inhibition of DNA replication is one of the causes of AA cyto-
toxicity.
3.5. Translation inhibition in response to AA treatment
We next performed polysome profiling to monitor translation ac-
tivity of mRNA in MDA-MB-231 cells upon AA treatment. Cellular RNAs
were extracted and fractioned in a 15–50% sucrose gradient. When
comparing nonpolysomal RNA and polysomal RNA quantities between
non-treated cells and cells treated with 10mM AA for 2 h, a significant
decrease in polysomal RNA (62 ± 5% vs 44 ± 2%) accompanied with
a significant increase in nonpolysomal RNA (38 ± 5% vs 56 ± 2%)
occurred, reflecting a decrease of cellular translation activity upon AA
treatment (Fig. 6A and B). Moreover, adding catalase (2000 U/ml) that
rescued cell viability rescued partially the cellular translation activity as
seen for polysomal RNA (44 ± 2% in AA-treated cells vs 53 ± 6% in
AA plus catalase-treated cells) and for nonpolysomal RNA (38 ± 5% vs
47 ± 6%) (Fig. 6A and B). Taken together, these data suggest that the
AA-induced inhibitory effect on mRNA translation contributes to AA
cytotoxicity.
3.6. H2O2 scavenging system including PRDX1 is linked to variable cellular
sensitivity to AA
The different sensitivity to AA among TNBC and non-TNBC cells
prompted us to identify gene and protein expressions that correlate
with AA anticancer activity. Pattern comparison using the NCI-60
CellMiner web tool [34,35] was performed to assess the correlation
between gene expression and AA cytotoxicity. Significant negative
Pearson's correlations (meaning that the more a gene is expressed, the
more cells are resistant to AA) were defined at r < −0.334 based on a
minimum of 35 informative cell lines, and P value < 0.05 in the ab-
sence of multiple comparisons. This analysis allowed us to identify 246
genes with transcript levels correlated negatively and significantly with
AA cytotoxicity (Supplementary Table 2). PTGR1 had the highest sig-
nificant correlation value (r=−0.608, P=0) and was already high-
lighted in our earlier work as a predictive biomarker for resistance of
breast cancer cell lines to auranofin/VitC combinational cytotoxicity
[28]. For AA alone, expressions of some antioxidant genes such as
TXNRD1 (r=−0.401, P=1.624× 10−3) and PRDX1 (r=−0.384,
P=2.678×10−3) also correlated negatively with AA cytotoxicity.
We performed a pathway analysis using the IPA software for the 246
genes. NRF2-mediated oxidative stress response was the first significant
canonical pathway enriched (Supplementary Fig. 2A). Top statistically
significant molecular and cellular pathways for these genes included
cellular movement and cell death and survival, among others. Finally,
the top networks of these genes included cancer, cell death and survival
and carbohydrate metabolism. Protein classification according to their
GO biological processes in DAVID database highlighted a significant
association with signal transduction, oxidation-reduction process, and
response to oxidative stress, among others (Supplementary Fig. 2B). All
these data directed us to conclude that oxidative stress response genes
play a role in the resistance of cancer cells to H2O2-mediated cyto-
toxicity of AA.
We wanted to ascertain that, for these genes, the predicted negative
correlation of their expression with AA activity according to NCI-60
database are indeed valid on breast cancer cell lines. We thus calculated
IC50 of AA on 13 breast cancer cell lines (Supplementary Fig. 3) and
correlated them with the retrieved gene expression data from the In-
stitut Curie database. Fig. 7A shows PRDX1 gene expression (mRNA)
distribution of 29 breast cancer cell lines. A correlation between AA
activity (log10IC50) and PRDX1 expression levels (log2) was statistically
significant and valid for most of the breast cancer cell lines studied
(Spearman's correlation r= 0.5769, P=0.0425) (Fig. 7B and C). By
knocking down PRDX1 gene, the highly resistant HCC-1954 became
significantly more sensitive to 10mM AA, MDA-MB-436 cells became
significantly more sensitive to 5 or 10mM AA (Fig. 7D and E), and
MDA-MB-231 cells became significantly more sensitive to 2.5mM AA
(Fig. 7F). Consistently, we previously showed that PRDX1 knockdown
sensitizes HeLa and A549 cancer cells toward ROS-generating antic-
ancer molecules [24,36]. More recently, other researchers reported
inhibitory effect of PRDX1-knockout on growth of mammary tumor in
mouse model, enhancing VitC cytotoxicity [37]. Finally, NCI-60 data
also indicate that lung cancer cells that are mostly resistant to AA have
high PRDX1 expression (Supplementary Fig. 4). Further experiments on
larger panel of cells in each cancer type are needed for achieve firm
conclusions on the predictive value of PRDX1 expression.
4. Discussion
Anticancer effect of VitC at pharmacologic concentrations has been
largely attributed to H2O2 extracellular generation from AA
[4,6–8,38,39]. However, one study reported that VitC selectively kills
KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH via
DHA [10]. Here we showed that AA displayed much higher cytotoxicity
than DHA in 13 breast cancer cell lines. Normal cells including HMEC,
human dermal fibroblasts and HUVEC were much less affected by AA
Fig. 3. Extracellular and intracellular H2O2 accumulation upon AA treatment in MDA-MB-231 cells. (A) Using Amplex-Red Kit, H2O2 concentration was
measured in the medium in the presence of MDA-MB-231 cells, without treatment or treated with 10mM AA alone, 10mM AA plus 2000 U/ml catalase, for 5min, ½
hour and 2 h. The same measurements were done on the medium without cells as controls. Quantifications are means ± SD of 3 independent experiments. (B) Cells
transiently expressing respectively cytoplasm-, nucleus-, mitochondria- and cell membrane-targeted HyPer were not treated or treated with 10mM AA alone or
together with 2000 U/ml catalase for 5min, ½ hour and 2 h. Treatment with 100 μM H2O2 for 20min was used as a positive control (PC). HyPer redox state was
evaluated by redox Western blot. ox, oxidized form; red, reduced form. Graphs show the quantification of oxidized HyPer (%) vs total HyPer protein. Quantifications
are means ± SD of 3 independent experiments. (C) Redox state of PRDX1 and PRDX3 was assessed using redox Western blot in cells without treatment or treated
with 10mM AA alone, 10mM AA plus 2000 U/ml catalase, for 5min, ½ hour and 2 h. Treatment with 100 μM H2O2 for 20min was used as a positive control (PC).
ox, oxidized form; red, reduced form. Quantifications of oxidized PRDX1 or PRDX3 (%) vs total protein in MDA-MB-231 cells are means ± SD of 3 independent
experiments. Statistical significance is assessed by ordinary one-way ANOVA with Tukey's multiple comparisons test. ****, P < 0.0001; ***, P < 0.001; **,
P < 0.01; *, P < 0.05.
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Fig. 4. Pathway, function and network analysis of the differentially oxidized cysteine-containing proteins identified by “redoxome” upon AA treatment.
The alterations of the oxidized proteome of cysteine-containing proteins, after 10mM AA treatment for ½ hour in MDA-MB-231 cells were analyzed by mass
spectrometry. 203 differentially oxidized proteins with P < 0.05 and a fold change over 1.5 in at least one of the two biological experiments were identified between
AA-treated and non-treated cells. (A) Significantly altered cysteine-containing proteins were mapped by the IPA analysis software. The top 5 significantly associated
canonical pathways, molecular and cellular functions and networks of these proteins are represented. (B) Altered proteins were classified according to their GO
biological process pathways in DAVID database. The top significantly (Fisher's modified test) associated biological processes are represented. **, P < 0.01; *,
P < 0.05.
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treatment. While most of breast cancer cell lines were sensitive to AA
similar to MDA-MB-231 cells, some cell lines, such as HCC-1954 and
MDA-MB-436, were more resistant. AA-induced cytotoxicity toward
MDA-MB-231 cells was entirely linked to extracellular H2O2 generation
and intracellular accumulation in different compartments together with
GSH oxidation.
Since H2O2 is the main player in AA cytotoxicity, we analyzed re-
doxome in MDA-MB-231 cells in order to reveal a general oxidation
spectrum of cysteine-containing proteins in response to AA. The short-
time AA treatment (½ hour) unlikely affects basal protein abundance
and therefore is less likely to bias protein oxidation data. Indeed,
Western blot for several randomly selected individual proteins that
showed a significant change in oxidation/reduction state of cysteines
following AA treatments indicated no change in total protein abun-
dance under the same condition as used in redoxome study (data not
shown). As expected, AA oxidizes antioxidant proteins such as PRDX1
Fig. 5. Effect AA treatment on cell cycles of MDA-MB-231 cells. (A) Non-treated (NT) cells, cells treated for 2 h with 10mM AA, 10mM AA plus 2000 U/ml
catalase were released in flesh medium. At various time points of post-treatment recovery (from 0 to 24 h), these cells were stained with BrdU for 1 h followed by PI
staining and FACS analysis. Dot plots of samples from 0, 6 and 24 h post-treatment recovery are presented with values of the percentages (%) of the population in
each phase of cell cycle (G0-G1, S, G2-M). (B) Histogram shows the percentages (%) of cells in G0-G1, S, G2-M phases at 0 h post-AA treatment as means ± SD
calculated from 3 independent experiments. Statistical significance is assessed by one-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05. (C) MDA-
MB-231 cells were labeled with BrdU for 1 h and then subjected to three treatment conditions for 2 h: non-treatment (NT), treated with 10mM AA, or 10mM AA plus
2000 U/ml catalase. Cells were then analyzed by flow cytometry after PI staining at different time points during recovery in growth media (0, 6 or 24 h).
Representative graphs of at least 3 experiments are shown.
Fig. 6. Effect AA treatment on polysome gradient
profiles of MDA-MB-231 cells. (A) Non-treated
(NT) cells, cells treated for 2 h with 10mM AA,
10mM AA plus 2000 U/ml catalase were incubated
for 15min with cycloheximide to stop ribosomal
elongation. Cellular RNA was extracted and frac-
tioned in a 15–50% sucrose gradient. Optical density
profiles (OD 254 nm) of polysome gradient profiles
are shown, and non-polysomal RNA corresponding to
fractions 1 to 8 (containing ribosomal RNAs present
in 40S, 60S, and 80S ribosomal complexes and free
mRNAs) and polysomal RNA corresponding to frac-
tions 9 to 18 (containing mRNAs bound to more than
one ribosome) are indicated. (B) The areas under the
curve (AUC) of the optical density profiles of non-
polysomal and polysomal RNA were measured, the
percentage of non-polysomal or polysomal RNA re-
lative to total was then calculated. Quantifications
are represented in graphs as means ± SD of 3 in-
dependent experiments. Statistical significance is
assessed by ordinary one-way ANOVA with Tukey's
multiple comparisons test. **, P < 0.01; *,
P < 0.05.
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Fig. 7. PRDX1 expression and its link to breast cancer cellular response to AA. (A) PRDX1 mRNA expression patterns in log2 values in 29 breast cancer cells
retrieved from publicly available transcriptomic datasets of the Institut Curie breast cancer cell lines. Mean and median values are shown as solid and dashed lines,
respectively. (B) Spearman's correlation analysis corresponding to PRDX1mRNA expression vs IC50 for AA on 13 breast cancer cell lines. IC50 values were calculated
from MTT assays for cell viability. Spearman's correlation was performed using GraphPad software. The 7 TNBC cell lines are indicated by green symbols and the 6
non-TNBC cell lines by purple symbols. The best-fit line is in solid orange line and the 95% confidence bands of the best-fit line are indicated in blue lines.
Mathematical parameters are represented next to the graphs. (C) logIC50 of AA for breast cancer cell lines and their PRDX1 mRNA expression in log2 values. (D-E-F)
MTT assay on HCC-1954, MDA-MB-436 and MDA-MB231 cells transiently transfected with PRDX1 specific siRNA or control siRNA for 48 h followed by treatments
with different concentrations of AA for 24 h. The insert is Western blot to verify efficiency of PRDX1 knockdown in siRNA transfected cells. Statistical significance is
assessed by two-way ANOVA with Sidak's multiple comparisons test. ****, P < 0.0001.
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and GGCT, very probably affecting the thioredoxin and glutathione
scavenging systems. Furthermore, AA alters the redox state of many
proteins implicated in the metabolic process, providing a rational ex-
planation for a set of previously reported data that AA induced meta-
bolic alterations, impairing glycolysis [10], pentose phosphate
pathway, glycolysis and tricarboxylic acid cycle [18], impairing the
Warburg metabolism and downregulating glucose transporters and
pyruvate kinase M2 in cancer cells [33].
Several proteins involved in RNA metabolism and related pathways
such as rRNA processing and translational initiation were significantly
enriched in redoxome data upon AA treatment. Consistently, we
showed a strong inhibitory effect of AA on mRNA translation in MDA-
MB-231 cells, indicating that mRNA translation inhibition is one of the
possible mechanisms responsible for oxidative stress-based AA cyto-
toxicity. This is in accordance with the fact that cells globally down-
regulate translation as quick adaptive response to stress [40]. In fact,
cells resort to translational reprogramming toward selective translation
of mRNAs encoding vital proteins, involved in survival and stress re-
covery, in an attempt to alleviate cellular burden under unfavorable
conditions [41]. It is worth noting that since recognizing the important
role played by deregulated translation in carcinogenesis [42], the re-
pression or blockage of protein synthesis has gained a significant in-
terest as a promising anticancer strategy [43,44]. Similarly, a set of
proteins implicated in DNA metabolism and related cell proliferation
pathway were found among the proteins with oxidized cysteine upon
AA treatment. Indeed, cell cycle of MDA-MB-231 cells was impaired
upon AA treatment for 2 h, suggesting potential involvement of DNA
replication inhibition in AA cytotoxicty. It is shown that AA, via H2O2
generation, induces time- and concentration-dependent genotoxic stress
and DNA damage and activates the ataxia telangiectasia mutated
(ATM)/adenosine monophosphate-activated protein kinase (AMPK)
pathway, all of which inhibit the mammalian target of rapamycin
(mTOR) signaling pathway connected to cell proliferation, inducing cell
death in ovarian cancer cells [19]. On the other hand, a direct impact of
VitC and vitamin K3 combination on ribonucleotide reductase (RNR)
was observed [45]. RNR activity was directly inhibited by the H2O2
generated along with the limited electron supply upon thioredoxin and
glutathione oxidation by the combination of the two molecules. RNR is
essential for de novo production of deoxyribonucleotides that is highly
needed in cancer cells, thus RNR could be the link between VitC, DNA
replication impairement and cancer cell death [45].
The mechanism by which VitC kills cancer cells while sparing
normal cells is not entirely clear. It could be linked to a differential
ability to metabolize H2O2 between normal and cancer cells [11], dif-
ferential SVCT2 expression [14], or to cancer cells altered redox-active
iron metabolism [15]. Our redoxome data and bioinformatics analysis
indicate that AA-generated H2O2 can target multiple pathways at the
same time, which might be particularly deleterious for cancer cells that
strongly rely on antioxidants and metabolic reprogramming for sur-
vival, contributing cytotoxic selectivity of AA in cancer vs normal cells.
Our bioinformatics analysis also revealed that proteins belonging to
the antioxidant system or NRF2-mediated oxidative stress response are
linked to variable cellular sensitivity to AA (Supplementary Fig. 2A).
Precisely, PRDX1 gene expression correlated significantly with the re-
sponse of breast cancer cell lines to AA, as cells with higher PRDX1
expression were more resistant to AA, and PRDX1 knockdown enhanced
cellular sensitivity to AA. PRDX1 is a key antioxidant that is directly
involved in H2O2 elimination, thus has a protective activity against AA-
generated H2O2 and could indeed be linked to AA resistance. PRDX1
prediction value to AA treatment outcome warrants further validation
in pre-clinical and clinical studies.
In summary, combined with previously reported data in the litera-
ture, this work provides insights on differential breast cancer cell line
response toward AA and DHA treatments (Fig. 8). We first showed an
extracellular generation of H2O2 by AA, but also an intracellular ac-
cumulation of H2O2. Intracellular H2O2 can be transported from the
extracellular medium by aquaporins or by passive diffusion across
plasma cellular membranes [46] but also generated by intracellular AA
upon import through SVCTs (mainly SVCT2) [47]. Although in breast
cancer cells, AA may not be imported by SVCT2, but only to mi-
tochondria via mitochondrial SVCT2 (mitSVCT2), AA can be oxidized
extracellularly to DHA and then imported through glucose transporters
to be reduced by GSH-dependent mechanisms to AA intracellularly
[48], consuming intracellular GSH [49,50]. AA treatment was cytotoxic
toward most of breast cancer cells tested and its higher cytotoxicity
compared to DHA was mainly linked to H2O2 generation. We identified
that proteins involved in DNA replication, cell cycle progression and
translations are among the principal targets of AA-induced cysteine
redox alterations and could be linked to AA-induced cytotoxicity.
Clinical data demonstrate that plasma VitC concentrations even
greater than 10mM are achievable in humans without causing apparent
adverse effects [51,52], and that pharmacological AA are well tolerated
by patients and can increase the efficacy of conventinal radiotharapy
and chemotherapy [15,23]. In our study, such AA concentrations were
cytotoxic toward most of breast cancer cell lines without severely af-
fecting normal cells, suggesting that VitC and VitC-based rational drug
combinations could be novel therapeutic opportunities for triple-ne-
gative breast cancer and other cancers with similar redox properties.
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Fig. 8. A model for AA- and DHA-induced cytotoxicity in breast cancer
cells. Upon AA-treatment, H2O2 is generated in the extracellular medium and
then imported to breast cancer cells by aquaporins or by passive diffusion
across plasma cellular membranes. Extracellularly generated H2O2 appears to
be the main source responsible for pro-oxidant properties of AA at pharmaco-
logic concentrations. Although AA may not be imported to cells from the ex-
ternal environment by sodium-dependent VitC transporters (mainly SVCT2) in
breast cancer, AA can be oxidized extracellularly into DHA and then imported
through glucose transporters (mainly GLUT1). DHA is reduced to AA in-
tracellularly by GSH-dependent mechanisms, consuming intracellular reduced
glutathione. AA thus generated further enhances H2O2 accumulation in dif-
ferent cellular compartments. A substantial increase in H2O2 causes redox
modifications of cysteine-containing proteins, including those involved in
translation and cell cycle progression. These effects contribute to AA-induced
cytotoxicity toward breast cancer cells.
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